PDF herunterladen
Exp Clin Endocrinol Diabetes 1995; 103(6): 391-397
DOI: 10.1055/s-0029-1211384
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Influence of somatostatin to biochemical parameters in patients with primary hyperparathyroidism

C. Hasse1 , A. Zielke1 , C. Bruns2 , M. Künneke3 , K. Ehlenz4 , M. G. Bachem5 , A. Hey6 , H. Kaffarnik4 , A. Gressner5 , M. Rothmund1
  • 1Department of Surgery, Philipps-University of Marburg, Germany
  • 2Sandoz Preclinical Research Division, Basel, Switzerland
  • 3Institute of Theoretical Surgery, Philipps-University of Marburg, Germany
  • 4Center of Internal Medicine, Department of Endocrinology and Matabolism, Philipps-University of Marburg, Germany
  • 5Division of Clinical Chemistry, Philipps-University of Marburg, Germany
  • 6Henning Berlin GmbH, Berlin, Germany
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
15. Juli 2009 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

Somatostatin (SRIF) is effective in the non-operative management of a variety endocrine tumors. A potential role of SRIF for treatment of patients with primary hyperparathyroidism (pHPT) has been suggested. In a controlled, prospective, triple-blinde, randomized clinical trial, the somatostatin analogue octreotide (SMS 201-995, Sandostatin®) was evaluated in 40 patients with well documented pHPT. Amongst the biochemical parameters, serum calcium and phosphate and levels of parathyroid hormone, calcitonin, and osteocalcin as well as octreotide were assessed before and for 4 hours after a single iv. application of 200 µg octreotide or placebo. SRIF-receptor autoradiography was performed in parathyroid tissue samples.

Baseline values revealed a constellation of biochemical parameters typically found in pHPT. Following 200 µg octreotide, no significant changes in any of the biochemical parameters investigated for were observed. Multivariate analysis was performed to identify patient subpopulations in which any given combination of laboratory parameters changed in response to either drug or placebo. However, no ‘responders’ to octreotide were identified. 45% of patients receiving octreotide, reported side effects. Parathyroid tissue samples were negative for SRIF-receptor expression.

It is concluded that a single dose iv. application of octreotide does not result in appreciable changes of biochemical parameters relevant in pHPT and carries a high rate of side effects. Furthermore, absence of SRIF-receptors in parathyroid tissue from patients with pHPT, together with lack of octreotide effects, suggests that somatostatin-analogues may not be effective in the non-operative therapy of pHPT.

Key words

Somatostatin - primary hyperparathyroidism - controlled clinical trial